0000200406false00002004062025-01-222025-01-220000200406us-gaap:CommonStockMember2025-01-222025-01-220000200406jnj:A1.150NotesDueNovember2028Member2025-01-222025-01-220000200406jnj:A3.20NotesDueNovember2032Member2025-01-222025-01-220000200406jnj:A1.650NotesDue2035Member2025-01-222025-01-220000200406jnj:A3.350NotesDueNovember2036Member2025-01-222025-01-220000200406jnj:A3.550NotesDueNovember2044Member2025-01-222025-01-22
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
January 22, 2025
Johnson & Johnson
(Exact name of registrant as specified in its charter)
| | | | | | | | |
| New Jersey | 1-3215 | 22-1024240 |
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
732-524-0400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | | | | |
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT
| | | | | | | | |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, Par Value $1.00 | JNJ | New York Stock Exchange |
| 1.150% Notes Due November 2028 | JNJ28 | New York Stock Exchange |
| 3.20% Notes Due November 2032 | JNJ32 | New York Stock Exchange |
| 1.650% Notes Due May 2035 | JNJ35 | New York Stock Exchange |
| 3.350% Notes Due November 2036 | JNJ36A | New York Stock Exchange |
| 3.550% Notes Due November 2044 | JNJ44 | New York Stock Exchange |
Item 2.02 Results of operations and financial condition
On January 22, 2025, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the fourth quarter and full year ended December 29, 2024.
Item 9.01 Financial statements and exhibits
(d) Exhibits.
| | | | | | | | |
| Exhibit No. | | Description of Exhibit |
| | |
| | |
| 104 | | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| JOHNSON & JOHNSON |
| (Registrant) |
| |
| By: | /s/ Robert J. Decker, Jr. |
| Robert J. Decker, Jr. Controller (Principal Accounting Officer) |
Exhibit 99.1
| | | | | | | | |
Media contact: media-relations@its.jnj.com | | Investor contact: investor-relations@its.jnj.com |
For immediate release
Johnson & Johnson reports Q4 and Full-Year 2024 results
•2024 Fourth-Quarter reported sales growth of 5.3% to $22.5 Billion with operational growth of 6.7%* and adjusted operational growth of 5.7%*
•2024 Fourth-Quarter Earnings per share (EPS) of $1.41 and Adjusted EPS of $2.04, both include $(0.22) due to acquired IPR&D charges related to V-Wave acquisition
•2024 Full-Year reported sales growth of 4.3% to $88.8 Billion with operational growth of 5.9%* and adjusted operational growth of 5.4%*. Operational growth excluding COVID-19 Vaccine of 7.0%*
•2024 Full-Year Earnings per share (EPS) of $5.79 and Adjusted EPS of $9.98, both include $(0.67) due to acquired IPR&D charges on various transactions throughout the year
•Significant pipeline progress including RYBREVANT + LAZCLUZE overall survival data, initiation of TAR-200 submission, and approval of investigational device exemption for our general surgery robotic system, OTTAVA
•Company issues guidance for 2025 with operational sales5 growth of 2.5% - 3.5%* and adjusted operational EPS of $10.75 - $10.95, reflecting strong growth of 8.7%* at the mid-point
New Brunswick, N.J. (January 22, 2025) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2024. "2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating pipeline and industry-leading investments in innovation,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “As a healthcare company, with a disease-centric approach, we are improving the standard of care in a broad range of diseases with high unmet need, including multiple myeloma, lung cancer, inflammatory bowel disease, and heart failure. With our strong financial foundation, differentiated portfolio and robust pipeline, we are well positioned to sustain the high pace of growth and innovation that is the hallmark of Johnson & Johnson.”
Unless otherwise noted, the financial results and earnings guidance included below reflect the continuing operations of Johnson & Johnson.
Overall financial results
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Q4 | | Full Year |
($ in Millions, expect EPS) | 2024 | 2023 | % Change | | 2024 | | 2023 | % Change |
Reported Sales |
| $22,520 22,,XXX | | $ 21,395 | 5.3% | | | $88,821 88, | | $ 85,159 | 4.3% |
Net Earnings | | $3,431 | | $4,132 | (17.0)% | | | $14,066 | | $13,326 | 5.6% |
EPS (diluted) | | $1.41 | | $1.70 | (17.1)% | | | $5.79 | | $5.20 | 11.3% |
|
| |
|
| Q4 | | Full Year |
Non-GAAP* ($ in Millions, except EPS) | 2024 | 2023 | % Change | | 2024 | 2023 | % Change |
Operational Sales1,2 | |
| |
| 6.7% | | |
| |
| 5.9% |
Adjusted Operational Sales1,3 | |
| |
| 5.7% | | |
| |
| 5.4% |
Adjusted Operational Sales1,3 ex. COVID-19 Vaccine | |
| |
| 5.9% | | |
| |
| 6.5% |
Adjusted Net Earnings1,4 | | $4,946 | | $5,562 | (11.1)% | | | $ 24,242 | | $ 25,409 | (4.6)% |
Adjusted EPS (diluted)1,4 | | $2.04 | | $2.29 | (10.9)% | | | $9.98 | | $9.92 | 0.6% |
Free Cash Flow6,7 | |
| | |
| | | ~$19,800 | | $18,248 |
|
1Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2Excludes the impact of translational currency
3Excludes the net impact of acquisitions and divestitures and translational currency
4Excludes intangible amortization expense and special items
5Excludes COVID-19 Vaccine
6Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings.
7Full year 2024 is estimated as of January 22, 2025. Full year 2023 includes approximately 8 months contribution from the Consumer Health segment.
Note: values may have been rounded
Regional sales results
| | | | | | | | | | | | | | | | | | | | |
Q4 |
|
|
| % Change |
|
($ in Millions) | 2024 | 2023 | Reported | Operational1,2 | Currency | Adjusted Operational1,3 |
U.S. | $13,204 | $12,009 | 10.0% | 10.0 | - | 8.6 |
International | 9,316 | 9,386 | (0.7) | 2.5 | (3.2) | 2.0 |
Worldwide | $22,520 | $21,395 | 5.3% | 6.7 | (1.4) | 5.7 |
|
|
|
|
|
|
|
Full Year |
|
|
| % Change |
|
($ in Millions) | 2024 | 2023 | Reported | Operational1,2 | Currency | Adjusted Operational1,3 |
U.S. | $50,302 | $46,444 | 8.3% | 8.3 | - | 7.6 |
International | 38,519 | 38,715 | (0.5) | 2.9 | (3.4) | 2.7 |
Worldwide | $88,821 | $85,159 | 4.3% | 5.9 | (1.6) | 5.4 |
1Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2Excludes the impact of translational currency
3Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
Segment sales results
| | | | | | | | | | | | | | | | | | | | |
Q4 |
|
|
| % Change |
|
($ in Millions) | 2024 | 2023 | Reported | Operational1,2 | Currency | Adjusted Operational1,3 |
Innovative Medicine | $14,332 | $13,722 | 4.4% | 6.1 | (1.7) | 6.3 |
MedTech | 8,188 | 7,673 | 6.7 | 7.6 | (0.9) | 4.6 |
Worldwide | $22,520 | $21,395 | 5.3% | 6.7 | (1.4) | 5.7 |
Full Year |
|
|
| % Change |
|
($ in Millions) | 2024 | 2023 | Reported | Operational1,2 | Currency | Adjusted Operational1,3 |
Innovative Medicine | $56,964 | $54,759 | 4.0% | 5.7 | (1.7) | 5.8 |
MedTech | 31,857 | 30,400 | 4.8 | 6.2 | (1.4) | 4.7 |
Worldwide | $88,821 | $85,159 | 4.3% | 5.9 | (1.6) | 5.4 |
1Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2Excludes the impact of translational currency
3Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
Full year 2024 segment commentary:
Operational sales* reflected below excludes the impact of translational currency.
Innovative Medicine
Innovative Medicine worldwide operational sales, excluding the COVID-19 Vaccine, grew 7.5%*. Growth was driven primarily by DARZALEX (daratumumab), ERLEADA (apalutamide), CARVYKTI (ciltacabtagene autoleucel), and Other Oncology in Oncology, TREMFYA (guselkumab) in Immunology, and SPRAVATO (esketamine) in Neuroscience. Growth was partially offset by STELARA (ustekinumab) in Immunology and Other Neuroscience in Neuroscience. Including the COVID-19 Vaccine, Innovative Medicine worldwide operational sales grew 5.7%*.
MedTech
MedTech worldwide operational sales grew 6.2%*, with net acquisitions and divestitures positively impacting growth by 1.5%. Growth was driven primarily by electrophysiology products and Abiomed in Cardiovascular, previously referred to as Interventional Solutions, and wound closure products in General Surgery.
Full-year 2025 guidance:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.
| | | | | | | | |
($ in Billions, except EPS) |
| January 2025 |
Adjusted Operational Sales1,2,5 Change vs. Prior Year / Mid-point |
| 2.0% – 3.0% / 2.5% |
Operational Sales2,5 / Mid-point Change vs. Prior Year / Mid-point |
| $90.9B – $91.7B / $91.3B 2.5% – 3.5% / 3.0% |
Estimated Reported Sales3,5/ Mid-point Change vs. Prior Year / Mid-point |
| $89.2B – $90.0B / $89.6B 0.5% – 1.5% / 1.0% |
Adjusted Operational EPS (Diluted)2,4 / Mid-point Change vs. Prior Year / Mid-point |
| $10.75 – $10.95 / $10.85 7.7% – 9.7% / 8.7% |
Adjusted EPS (Diluted)3,4 / Mid-point Change vs. Prior Year / Mid-point |
| $10.50 – $10.70 / $10.60 5.2% – 7.2% / 6.2% |
1Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2Non-GAAP financial measure; excludes the impact of translational currency
3Calculated using Euro Average Rate: January 2025 = $1.04 (Illustrative purposes only)
4Non-GAAP financial measure; excludes intangible amortization expense and special items
5Excludes COVID-19 Vaccine
Note: percentages may have been rounded
Other modeling considerations will be provided on the webcast.
Notable announcements in the quarter:
The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company’s website at News Releases, as well as Innovative Medicine News Center, MedTech News & Events, and www.factsabouttalc.com.
| | | | | | | | | | | |
| Regulatory | SPRAVATO (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression1 | Press Release | |
| European Commission approves LAZCLUZE (lazertinib) in combination with RYBREVANT (amivantamab) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer1 | Press Release | |
| New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer1 | Press Release | |
| Johnson & Johnson MedTech Announces CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCH SF Catheter1 | Press Release | |
| Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis1 | Press Release | |
| Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease1 | Press Release | |
| European Commission approves RYBREVANT (amivantamab) in combination with LAZCLUZE (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer | Press Release | |
| Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA (ibrutinib) in adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplant | Press Release | |
| U.S. FDA Expands Indication for Impella Heart Pumps to Treat Pediatric Patients | Press Release | |
| Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA (guselkumab) | Press Release | |
| Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor | Press Release | |
| Johnson & Johnson MedTech Receives IDE Approval for OTTAVA Robotic Surgical System | Press Release | |
| Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease | Press Release | |
| Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO / DARZALEX as subcutaneous monotherapy for high-risk smoldering multiple myeloma | Press Release | |
| DARZALEX (daratumumab)-SC based quadruplet regimen approved by the European Commission for patients with newly diagnosed multiple myeloma who are transplant-eligible | Press Release | |
| | | | | | | | | | | |
| Data Releases | RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib1 | Press Release | |
| Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting | Press Release | |
| Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results | Press Release | |
| Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024 | Press Release | |
| Shockwave Medical Unveils First Clinical Outcomes of New IVL Platform in Late-Breaking Presentation at VIVA 2024 | Press Release | |
| TREMFYA (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease | Press Release | |
| New SPECTREM study findings reveal TREMFYA (guselkumab) effectively clears overlooked and undertreated plaque psoriasis | Press Release | |
| Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress | Press Release | |
| Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study | Press Release | |
| Product Launch | MENTOR MemoryGel Enhance Breast Implant Receives FDA Approval for Largest Size Breast Implants for Reconstruction | Press Release | |
Johnson & Johnson MedTech Receives FDA Approval for the VARIPULSE Pulsed Field Ablation Platform for the Treatment of Atrial Fibrillation2 | Press Release | |
| Other | Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.1 | Press Release | |
1Subsequent to the quarter
2On January 5, 2025, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE cases. More information can be found in the Statement on VARIPULSE.
Webcast information:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:00 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations.
About Johnson & Johnson:
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com.
Non-GAAP financial measures:
* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results.
Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results.
Note to investors concerning forward-looking statements:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; and the Company’s ability to realize the anticipated benefits from the separation of Kenvue Inc. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Exhibit 99.2
Johnson & Johnson and subsidiaries
Supplementary sales data
| | | | | | | | | | | | | | | | | |
| (Unaudited; Dollars in Millions) | FOURTH QUARTER |
| | | Percent Change |
| Sales to customers by geographic area | 2024 | 2023 | Total | Operations | Currency |
| U.S. | $13,204 | | 12,009 | | 10.0 | % | 10.0 | | — | |
| Europe | 4,921 | | 4,962 | | (0.8) | | (0.2) | | (0.6) | |
| Western Hemisphere excluding U.S. | 1,135 | | 1,166 | | (2.7) | | 17.6 | | (20.3) | |
| Asia-Pacific, Africa | 3,260 | | 3,258 | | 0.1 | | 0.9 | | (0.8) | |
| International | 9,316 | | 9,386 | | (0.7) | | 2.5 | | (3.2) | |
| Worldwide | $22,520 | | 21,395 | | 5.3 | % | 6.7 | | (1.4) | |
| | | | | |
| | | | | |
Johnson & Johnson and subsidiaries
Supplementary sales data
| | | | | | | | | | | | | | | | | |
| (Unaudited; Dollars in Millions) | FOURTH QUARTER |
| | | Percent Change |
| Sales to customers by geographic area (ex. COVID-19 Vaccine) | 2024 | 2023 | Total | Operations | Currency |
| U.S.* | $13,204 | | 12,009 | | 10.0 | % | 10.0 | | — | |
Europe(1) | 4,921 | | 4,918 | | 0.1 | | 0.7 | | (0.6) | |
| Western Hemisphere excluding U.S.* | 1,135 | | 1,166 | | (2.7) | | 17.6 | | (20.3) | |
| Asia-Pacific, Africa* | 3,260 | | 3,258 | | 0.1 | | 0.9 | | (0.8) | |
| International | 9,316 | | 9,342 | | (0.3) | | 2.9 | | (3.2) | |
| Worldwide | $22,520 | | 21,351 | | 5.5 | % | 6.9 | | (1.4) | |
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Refer to supplemental sales information schedules
*No COVID-19 Vaccine Sales
Johnson & Johnson and subsidiaries
Supplementary sales data
| | | | | | | | | | | | | | | | | |
| (Unaudited; Dollars in Millions) | TWELVE MONTHS |
| | | Percent Change |
| Sales to customers by geographic area | 2024 | 2023 | Total | Operations | Currency |
| U.S. | $50,302 | | 46,444 | | 8.3 | % | 8.3 | | — | |
| Europe | 20,212 | | 20,410 | | (1.0) | | (0.6) | | (0.4) | |
| Western Hemisphere excluding U.S. | 4,714 | | 4,549 | | 3.6 | | 20.4 | | (16.8) | |
| Asia-Pacific, Africa | 13,593 | | 13,756 | | (1.2) | | 2.3 | | (3.5) | |
| International | 38,519 | | 38,715 | | (0.5) | | 2.9 | | (3.4) | |
| Worldwide | $88,821 | | 85,159 | | 4.3 | % | 5.9 | | (1.6) | |
| | | | | |
| | | | | |
Johnson & Johnson and subsidiaries
Supplementary sales data
| | | | | | | | | | | | | | | | | |
| (Unaudited; Dollars in Millions) | TWELVE MONTHS |
| | | Percent Change |
| Sales to customers by geographic area (ex. COVID-19 Vaccine) | 2024 | 2023 | Total | Operations | Currency |
| U.S.* | $50,302 | | 46,444 | | 8.3 | % | 8.3 | | — | |
Europe(1) | 20,014 | | 19,293 | | 3.7 | | 4.1 | | (0.4) | |
| Western Hemisphere excluding U.S.* | 4,714 | | 4,549 | | 3.6 | | 20.4 | | (16.8) | |
| Asia-Pacific, Africa* | 13,593 | | 13,756 | | (1.2) | | 2.3 | | (3.5) | |
| International | 38,321 | | 37,598 | | 1.9 | | 5.5 | | (3.6) | |
| Worldwide | $88,623 | | 84,042 | | 5.5 | % | 7.0 | | (1.5) | |
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Refer to supplemental sales information schedules
*No COVID-19 Vaccine Sales
Johnson & Johnson and subsidiaries
Supplementary sales data
| | | | | | | | | | | | | | | | | | | | |
| (Unaudited; Dollars in Millions) | FOURTH QUARTER |
| | | Percent Change |
| Sales to customers by segment of business | | 2024 | 2023 | Total | Operations | Currency |
Innovative Medicine (1) | | | | | | |
| U.S. | | $ | 8,977 | | 8,079 | | 11.1 | % | 11.1 | | — | |
| International | | 5,355 | | 5,643 | | (5.1) | | (1.0) | | (4.1) | |
| | 14,332 | | 13,722 | | 4.4 | | 6.1 | | (1.7) | |
Innovative Medicine excluding COVID-19 Vaccine (1) | | | | | | |
| U.S. | | 8,977 | | 8,079 | | 11.1 | | 11.1 | | — | |
| International | | 5,355 | | 5,599 | | (4.4) | | (0.3) | | (4.1) | |
| | 14,332 | | 13,678 | | 4.8 | | 6.5 | | (1.7) | |
| MedTech | | | | | | |
| U.S. | | 4,227 | | 3,930 | | 7.6 | | 7.6 | | — | |
| International | | 3,961 | | 3,743 | | 5.8 | | 7.6 | | (1.8) | |
| | 8,188 | | 7,673 | | 6.7 | | 7.6 | | (0.9) | |
| U.S. | | 13,204 | | 12,009 | | 10.0 | | 10.0 | | — | |
| International | | 9,316 | | 9,386 | | (0.7) | | 2.5 | | (3.2) | |
| Worldwide | | 22,520 | | 21,395 | | 5.3 | | 6.7 | | (1.4) | |
| U.S. | | 13,204 | | 12,009 | | 10.0 | | 10.0 | | — | |
| International | | 9,316 | | 9,342 | | (0.3) | | 2.9 | | (3.2) | |
Worldwide excluding COVID-19 Vaccine (1) | | $ | 22,520 | | 21,351 | | 5.5 | % | 6.9 | | (1.4) | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1)Refer to supplemental sales information schedules.
Johnson & Johnson and subsidiaries
Supplementary sales data
| | | | | | | | | | | | | | | | | |
| (Unaudited; Dollars in Millions) | TWELVE MONTHS |
| | | Percent Change |
| Sales to customers by segment of business | 2024 | 2023 | Total | Operations | Currency |
Innovative Medicine (1) | | | | | |
| U.S. | $33,970 | | 31,169 | | 9.0 | % | 9.0 | | — | |
| International | 22,994 | | 23,590 | | (2.5) | | 1.3 | | (3.8) | |
| 56,964 | | 54,759 | | 4.0 | | 5.7 | | (1.7) | |
Innovative Medicine excluding COVID-19 Vaccine (1) | | | | | |
| U.S. | 33,970 | | 31,169 | | 9.0 | | 9.0 | | — | |
| International | 22,796 | | 22,473 | | 1.4 | | 5.5 | | (4.1) | |
| 56,766 | | 53,642 | | 5.8 | | 7.5 | | (1.7) | |
| MedTech | | | | | |
| U.S. | 16,332 | | 15,275 | | 6.9 | | 6.9 | | — | |
| International | 15,525 | | 15,125 | | 2.6 | | 5.4 | | (2.8) | |
| 31,857 | | 30,400 | | 4.8 | | 6.2 | | (1.4) | |
| U.S. | 50,302 | | 46,444 | | 8.3 | | 8.3 | | — | |
| International | 38,519 | | 38,715 | | (0.5) | | 2.9 | | (3.4) | |
| Worldwide | 88,821 | | 85,159 | | 4.3 | | 5.9 | | (1.6) | |
| U.S. | 50,302 | | 46,444 | | 8.3 | | 8.3 | | — | |
| International | 38,321 | | 37,598 | | 1.9 | | 5.5 | | (3.6) | |
Worldwide excluding COVID-19 Vaccine (1) | $88,623 | | 84,042 | | 5.5 | % | 7.0 | | (1.5) | |
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1)Refer to supplemental sales information schedules.
Johnson & Johnson and subsidiaries
Condensed consolidated statement of earnings
| | | | | | | | | | | | | | | | | |
| (Unaudited; in Millions Except Per Share Figures) | FOURTH QUARTER |
| 2024 | 2023 | Percent
Increase
(Decrease) |
| Amount | Percent
to Sales | Amount | Percent
to Sales |
| Sales to customers | $ | 22,520 | | 100.0 | | $21,395 | | 100.0 | | 5.3 | |
| Cost of products sold | 7,128 | | 31.6 | | 6,798 | | 31.8 | | 4.9 | |
| Gross Profit | 15,392 | | 68.4 | | 14,597 | | 68.2 | | 5.4 | |
| Selling, marketing and administrative expenses | 6,453 | | 28.6 | | 5,810 | | 27.1 | | 11.1 | |
| Research and development expense | 5,298 | | 23.5 | | 4,480 | | 20.9 | | 18.3 | |
| In-process research and development impairments | 17 | | 0.1 | | 58 | | 0.3 | | |
| Interest (income) expense, net | (144) | | (0.6) | | (212) | | (1.0) | | |
| Other (income) expense, net | (161) | | (0.7) | | (421) | | (2.0) | | |
| Restructuring | 42 | | 0.2 | | 56 | | 0.3 | | |
| Earnings before provision for taxes on income | 3,887 | | 17.3 | | 4,826 | | 22.6 | | (19.5) | |
| Provision for taxes on income | 456 | | 2.1 | | 694 | | 3.3 | | (34.3) | |
| Net earnings from Continuing Operations | $3,431 | | 15.2 | | $4,132 | | 19.3 | | (17.0) | |
| Net earnings/(loss) from Discontinued Operations, net of tax | — | | | (83) | | | |
| Net earnings | $3,431 | | | $4,049 | | | |
| | | | | |
| Net earnings per share (Diluted) from Continuing Operations | $ | 1.41 | | | $ | 1.70 | | | (17.1) | |
| Net earnings/(loss) per share (Basic) from Discontinued Operations* | $ | — | | | $ | (0.03) | | | |
| | | | | |
| Average shares outstanding (Diluted) | 2,427.1 | | | 2,430.7 | | | |
| | | | | |
| Effective tax rate from Continuing Operations | 11.7 | % | | 14.4 | % | | |
| | | | | |
Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1) (A) | | |
| Earnings before provision for taxes on income from Continuing Operations | $ | 5,421 | | 24.1 | $ | 6,237 | | 29.2 | (13.1) | |
| Net earnings from Continuing Operations | $ | 4,946 | | 22.0 | $ | 5,562 | | 26.0 | (11.1) | |
| Net earnings per share (Diluted) from Continuing Operations | $ | 2.04 | | | $ | 2.29 | | | (10.9) | |
| Effective tax rate from Continuing Operations | 8.8 | % | | 10.8 | % | | |
* Basic shares of 2,407.2 are used to calculate loss per share in the fourth quarter of 2023 as use of diluted shares when in a loss position would be anti-dilutive.
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings from continuing operations before provision for taxes on income," "adjusted net earnings from continuing operations," "adjusted net earnings per share (diluted) from continuing operations," and "adjusted effective tax rate from continuing operations" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings from continuing operations before provision for taxes on income, net earnings from continuing operations, net earnings per share (diluted) from continuing operations, and effective tax rate from continuing operations on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings from continuing operations before provision for taxes on income, net earnings from continuing operations, net earnings per share (diluted) from continuing operations, and effective tax rate from continuing operations prepared in accordance with GAAP, adjusted earnings from continuing operations before provision for taxes on income, adjusted net earnings from continuing operations, adjusted net earnings per share (diluted) from continuing operations, and adjusted effective tax rate from continuing operations may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.
Johnson & Johnson and subsidiaries
Condensed consolidated statement of earnings
| | | | | | | | | | | | | | | | | |
| (Unaudited; in Millions Except Per Share Figures) | TWELVE MONTHS |
| 2024 | 2023 | Percent Increase (Decrease) |
| Amount | Percent to Sales | Amount | Percent to Sales |
| Sales to customers | $ | 88,821 | | 100.0 | | $ | 85,159 | | 100.0 | | 4.3 | |
| Cost of products sold | 27,471 | | 30.9 | | 26,553 | | 31.2 | | 3.5 | |
| Gross Profit | 61,350 | | 69.1 | | 58,606 | | 68.8 | | 4.7 | |
| Selling, marketing and administrative expenses | 22,869 | | 25.7 | | 21,512 | | 25.2 | | 6.3 | |
| Research and development expense | 17,232 | | 19.4 | | 15,085 | | 17.7 | | 14.2 | |
| In-process research and development impairments | 211 | | 0.2 | | 313 | | 0.4 | | |
| Interest (income) expense, net | (577) | | (0.6) | | (489) | | (0.6) | | |
| Other (income) expense, net | 4,694 | | 5.3 | | 6,634 | | 7.8 | | |
| Restructuring | 234 | | 0.3 | | 489 | | 0.6 | | |
| Earnings before provision for taxes on income | 16,687 | | 18.8 | | 15,062 | | 17.7 | | 10.8 | |
| Provision for taxes on income | 2,621 | | 3.0 | | 1,736 | | 2.1 | | 51.0 | |
| Net earnings from Continuing Operations | $14,066 | | 15.8 | | $ | 13,326 | | 15.6 | | 5.6 | |
| Net earnings from Discontinued Operations, net of tax | — | | | 21,827 | | | |
| Net earnings | $14,066 | | | $ | 35,153 | | | |
| | | | | |
| Net earnings per share (Diluted) from Continuing Operations | $ | 5.79 | | | $ | 5.20 | | | 11.3 | |
| Net earnings per share (Diluted) from Discontinued Operations | $ | — | | | $ | 8.52 | | | |
| | | | | |
| Average shares outstanding (Diluted) | 2,429.4 | | | 2,560.4 | | | |
| | | | | |
| Effective tax rate from Continuing Operations | 15.7 | % | | 11.5 | % | | |
| | | | | |
Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1) (A) | | |
| Earnings before provision for taxes on income from Continuing Operations | $ | 28,979 | | 32.6 | | $ | 29,811 | | 35.0 | | (2.8) | |
| Net earnings from Continuing Operations | $ | 24,242 | | 27.3 | | $ | 25,409 | | 29.8 | | (4.6) | |
| Net earnings per share (Diluted) from Continuing Operations | $ | 9.98 | | | $ | 9.92 | | | 0.6 | |
| Effective tax rate from Continuing Operations | 16.3 | % | | 14.8 | % | | |
(1)See Reconciliation of Non-GAAP Financial Measures.
(A)NON-GAAP FINANCIAL MEASURES "Adjusted earnings from continuing operations before provision for taxes on income," "adjusted net earnings from continuing operations," "adjusted net earnings per share (diluted) from continuing operations," and "adjusted effective tax rate from continuing operations" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings from continuing operations before provision for taxes on income, net earnings from continuing operations, net earnings per share (diluted) from continuing operations, and effective tax rate from continuing operations on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings from continuing operations before provision for taxes on income, net earnings from continuing operations, net earnings per share (diluted) from continuing operations, and effective tax rate from continuing operations prepared in accordance with GAAP, adjusted earnings from continuing operations before provision for taxes on income, adjusted net earnings from continuing operations, adjusted net earnings per share (diluted) from continuing operations, and adjusted effective tax rate from continuing operations may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.
Johnson & Johnson and subsidiaries
Reconciliation of non-GAAP financial measures
| | | | | | | | | | | | | | |
| Fourth Quarter |
| (Dollars in Millions Except Per Share Data) | 2024 | | 2023 |
| Net Earnings from Continuing Operations, after tax- as reported | | $3,431 | | | $4,132 | |
| | | | |
| Pre-tax Adjustments | | | | |
| Litigation related | | (16) | | | 166 | |
| Intangible Asset Amortization expense | | 1,171 | | | 1,148 | |
COVID-19 Vaccine related costs 1 | | 23 | | | 10 | |
Restructuring related 2 | | 62 | | | 139 | |
Medical Device Regulation 3 | | 47 | | | 88 | |
| Acquisition, integration and divestiture related | | 298 | | | 237 | |
| (Gains)/losses on securities | | (68) | | | (435) | |
| IPR&D impairments | | 17 | | | 58 | |
| | | | |
| Tax Adjustments | | | | |
Tax impact on special item adjustments 4 | | (80) | | | 75 | |
| Tax legislation and other tax related | | 61 | | | (56) | |
| Adjusted Net Earnings from Continuing Operations, after tax | | $4,946 | | | $5,562 | |
| Average shares outstanding (Diluted) | | 2,427.1 | | | 2,430.7 | |
| Adjusted net earnings per share from Continuing Operations (Diluted) | | $2.04 | | | $2.29 | |
| Operational adjusted net earnings per share from Continuing Operations (Diluted) | | $2.05 | | | |
Notes:
1COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments which was completed in Q4 2024.
2In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expense of $102 million Q4 2024 YTD and $55 million in the fiscal fourth quarter of 2023 ($479 million Q4 2023 YTD) includes the termination of partnered and non-partnered program costs, asset impairments and asset divestments. This program was completed in Q4 2024.
In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense of $60 million in the fiscal fourth quarter of 2024 ($167 million Q4 2024 YTD) and $84 million in the fiscal fourth quarter of 2023 ($319 million Q4 2023 YTD) primarily includes costs related to market and product exits.
3European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance. The implementation was substantially completed as of Q4 2024, and ongoing costs will be reflected in MedTech's operating results beginning in 2025.
4The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.
Johnson & Johnson and subsidiaries
Reconciliation of non-GAAP financial measures
| | | | | | | | | | | | | | |
| Twelve Months Ended |
| (Dollars in Millions Except Per Share Data) | 2024 | 2023 |
| Net Earnings from Continuing Operations, after tax- as reported | | $14,066 | | | $13,326 | |
| | | | |
| Pre-tax Adjustments | | | | |
| Litigation related | | 5,450 | | | 7,152 | |
| Intangible Asset Amortization expense | | 4,526 | | | 4,532 | |
COVID-19 Vaccine related costs 1 | | 100 | | | 663 | |
Restructuring related 2 | | 269 | | | 798 | |
Medical Device Regulation 3 | | 204 | | | 311 | |
| Acquisition, integration and divestiture related | | 1,226 | | | 339 | |
| (Gains)/losses on securities | | 306 | | | 641 | |
| IPR&D impairments | | 211 | | | 313 | |
| | | | |
| Tax Adjustments | | | | |
Tax impact on special item adjustments 4 | | (2,135) | | | (2,694) | |
| Tax legislation and other tax related | | 19 | | | 28 | |
| Adjusted Net Earnings from Continuing Operations, after tax | | $24,242 | | | $25,409 | |
| Average shares outstanding (Diluted) | | 2,429.4 | | | 2,560.4 | |
| Adjusted net earnings per share from Continuing Operations (Diluted) | | $9.98 | | | $9.92 | |
| Operational adjusted net earnings per share from Continuing Operations (Diluted) | | $9.99 | | | |
Notes:
1COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments which was completed in Q4 2024.
2In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expense of $102 million Q4 2024 YTD and $55 million in the fiscal fourth quarter of 2023 ($479 million Q4 2023 YTD) includes the termination of partnered and non-partnered program costs, asset impairments and asset divestments. This program was completed in Q4 2024.
In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense of $60 million in the fiscal fourth quarter of 2024 ($167 million Q4 2024 YTD) and $84 million in the fiscal fourth quarter of 2023 ($319 million Q4 2023 YTD) primarily includes costs related to market and product exits.
3European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance. The implementation was substantially completed as of Q4 2024, and ongoing costs will be reflected in MedTech's operating results beginning in 2025.
4The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.
Johnson & Johnson and subsidiaries
Reconciliation of non-GAAP financial measures
Adjusted operational sales growth(A)
Fourth quarter 2024 actual vs. 2023 actual
| | | | | | | | | | | | | | | | | | | | |
| Segments |
| | Innovative Medicine | | MedTech | | Total |
| WW As Reported | | 4.4 | % | | 6.7 | % | | 5.3 | % |
| U.S. | | 11.1 | % | | 7.6 | % | | 10.0 | % |
| International | | (5.1 | %) | | 5.8 | % | | (0.7 | %) |
| | | | | | |
| WW Currency | | (1.7) | | (0.9) | | (1.4) |
| U.S. | | — | | — | | — |
| International | | (4.1) | | (1.8) | | (3.2) |
| | | | | | |
| WW Operational | | 6.1 | % | | 7.6 | % | | 6.7 | % |
| U.S. | | 11.1 | % | | 7.6 | % | | 10.0 | % |
| International | | (1.0 | %) | | 7.6 | % | | 2.5 | % |
| | | | | | |
| Shockwave | | | | (3.4) | | (1.2) |
| U.S. | | | | (5.1) | | (1.7) |
| International | | | | (1.5) | | (0.6) |
| | | | | | |
| All Other Acquisitions and Divestitures (A&D) | | 0.2 | | 0.4 | | 0.2 |
| U.S. | | 0.1 | | 0.8 | | 0.3 |
| International | | 0.3 | | 0.0 | | 0.1 |
| | | | | | |
| WW Adjusted Operational Ex A&D | | 6.3 | % | | 4.6 | % | | 5.7 | % |
| U.S. | | 11.2 | % | | 3.3 | % | | 8.6 | % |
| International | | (0.7 | %) | | 6.1 | % | | 2.0 | % |
| | | | | | |
| COVID-19 Vaccine | | 0.4 | | | | 0.2 |
| U.S. | | 0.0 | | | | 0.0 |
| International | | 0.7 | | | | 0.4 |
| | | | | | |
| WW Adjusted Operational Ex A&D & COVID-19 Vaccine | | 6.7 | % | | 4.6 | % | | 5.9 | % |
| U.S. | | 11.2 | % | | 3.3 | % | | 8.6 | % |
| International | | 0.0 | % | | 6.1 | % | | 2.4 | % |
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.
Johnson & Johnson and subsidiaries
Reconciliation of non-GAAP financial measures
Adjusted operational sales growth(A)
Twelve months 2024 actual vs. 2023 actual
| | | | | | | | | | | | | | | | | | | | |
| Segments |
| | Innovative Medicine | | MedTech | | Total |
| WW As Reported | | 4.0 | % | | 4.8 | % | | 4.3 | % |
| U.S. | | 9.0 | % | | 6.9 | % | | 8.3 | % |
| International | | (2.5) | % | | 2.6 | % | | (0.5) | % |
| | | | | | |
| WW Currency | | (1.7) | | (1.4) | | (1.6) |
| U.S. | | — | | — | | — |
| International | | (3.8) | | (2.8) | | (3.4) |
| | | | | | |
| WW Operational | | 5.7 | % | | 6.2 | % | | 5.9 | % |
| U.S. | | 9.0 | % | | 6.9 | % | | 8.3 | % |
| International | | 1.3 | % | | 5.4 | % | | 2.9 | % |
| | | | | | |
| Shockwave | | | | (1.9) | | (0.7) |
| U.S. | | | | (2.9) | | (1.0) |
| International | | | | (0.8) | | (0.3) |
| | | | | | |
| All Other Acquisitions and Divestitures (A&D) | | 0.1 | | 0.4 | | 0.2 |
| U.S. | | 0.1 | | 0.8 | | 0.3 |
| International | | 0.2 | | 0.1 | | 0.1 |
| | | | | | |
| WW Adjusted Operational Ex A&D | | 5.8 | % | | 4.7 | % | | 5.4 | % |
| U.S. | | 9.1 | % | | 4.8 | % | | 7.6 | % |
| International | | 1.5 | % | | 4.7 | % | | 2.7 | % |
| | | | | | |
| COVID-19 Vaccine | | 1.8 | | | | 1.1 |
| U.S. | | 0.0 | | | | 0.0 |
| International | | 4.2 | | | | 2.6 |
| | | | | | |
| WW Adjusted Operational Ex A&D & COVID-19 Vaccine | | 7.6 | % | | 4.7 | % | | 6.5 | % |
| U.S. | | 9.1 | % | | 4.8 | % | | 7.6 | % |
| International | | 5.7 | % | | 4.7 | % | | 5.3 | % |
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.
Johnson & Johnson
Segment sales
(Dollars in Millions)
| | | | | | | | | | | | | | | | | | | | | | | |
| FOURTH QUARTER |
| | | | | % Change |
| 2024 | | 2023 | | Reported | Operational(1) | Currency |
INNOVATIVE MEDICINE SEGMENT(2) | | | | | | | |
| IMMUNOLOGY | | | | | | | |
| US | $2,856 | | | 3,033 | | | (5.9) | % | (5.9) | % | — | % |
| Intl | 1,383 | | | 1,562 | | | (11.5) | | (6.5) | | (5.0) | |
| WW | 4,238 | | | 4,595 | | | (7.8) | | (6.1) | | (1.7) | |
| | | | | | | |
| REMICADE | | | | | | | |
| US | 231 | | | 294 | | | (21.4) | | (21.4) | | — | |
US Exports(3) | 9 | | | 35 | | | (73.3) | | (73.3) | | — | |
| Intl | 117 | | | 100 | | | 16.5 | | 22.9 | | (6.4) | |
| WW | 359 | | | 429 | | | (16.5) | | (15.0) | | (1.5) | |
| | | | | | | |
| SIMPONI / SIMPONI ARIA | | | | | | | |
| US | 262 | | | 258 | | | 1.3 | | 1.3 | | — | |
| Intl | 321 | | | 244 | | | 32.1 | | 44.2 | | (12.1) | |
| WW | 583 | | | 502 | | | 16.2 | | 22.1 | | (5.9) | |
| | | | | | | |
| STELARA | | | | | | | |
| US | 1,699 | | | 1,786 | | | (4.9) | | (4.9) | | — | |
| Intl | 650 | | | 967 | | | (32.7) | | (29.6) | | (3.1) | |
| WW | 2,349 | | | 2,753 | | | (14.7) | | (13.6) | | (1.1) | |
| | | | | | | |
| TREMFYA | | | | | | | |
| US | 654 | | | 657 | | | (0.6) | | (0.6) | | — | |
| Intl | 295 | | | 252 | | | 16.9 | | 21.7 | | (4.8) | |
| WW | 949 | | | 910 | | | 4.2 | | 5.6 | | (1.4) | |
| | | | | | | |
| OTHER IMMUNOLOGY | | | | | | | |
| US | 0 | | | 2 | | | * | * | — | |
| Intl | 0 | | | 0 | | | — | | — | | — | |
| WW | 0 | | | 2 | | | * | * | * |
| | | | | | | |
| INFECTIOUS DISEASES | | | | | | | |
| US | 331 | | | 353 | | | (6.4) | | (6.4) | | — | |
| Intl | 443 | | | 498 | | | (11.2) | | (9.8) | | (1.4) | |
| WW | 774 | | | 852 | | | (9.2) | | (8.4) | | (0.8) | |
| | | | | | | |
| COVID-19 VACCINE | | | | | | | |
| US | 0 | | | 0 | | | — | | — | | — | |
| Intl | 0 | | | 44 | | | * | * | * |
| WW | 0 | | | 44 | | | * | * | * |
| | | | | | | |
| EDURANT / rilpivirine | | | | | | | |
| US | 7 | | | 9 | | | (10.1) | | (10.1) | | — | |
| Intl | 315 | | | 299 | | | 5.0 | | 5.6 | | (0.6) | |
| WW | 322 | | | 307 | | | 4.6 | | 5.1 | | (0.5) | |
| | | | | | | |
| PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | | | | | | | |
| US | 321 | | | 341 | | | (5.8) | | (5.8) | | — | |
| Intl | 86 | | | 98 | | | (12.9) | | (8.9) | | (4.0) | |
| WW | 407 | | | 439 | | | (7.4) | | (6.5) | | (0.9) | |
| | | | | | | |
| OTHER INFECTIOUS DISEASES | | | | | | | |
| US | 1 | | | 4 | | | (53.1) | | (53.1) | | — | |
| Intl | 43 | | | 58 | | | (24.2) | | (22.4) | | (1.8) | |
| WW | 45 | | | 62 | | | (26.1) | | (24.4) | | (1.7) | |
See footnotes at end of schedule
Johnson & Johnson
Segment sales
(Dollars in Millions)
| | | | | | | | | | | | | | | | | | | | | | | |
| FOURTH QUARTER |
| | | | | % Change |
| 2024 | | 2023 | | Reported | Operational(1) | Currency |
INNOVATIVE MEDICINE SEGMENT(2)(Continued) | | | | | | | |
| NEUROSCIENCE | | | | | | | |
| US | $1,148 | | | 1,022 | | | 12.3 | % | 12.3 | % | — | % |
| Intl | 628 | | | 780 | | | (19.6) | | (16.8) | | (2.8) | |
| WW | 1,775 | | | 1,801 | | | (1.5) | | (0.3) | | (1.2) | |
| | | | | | | |
| CONCERTA / methylphenidate | | | | | | | |
| US | 33 | | | 39 | | | (12.8) | | (12.8) | | — | |
| Intl | 125 | | | 142 | | | (11.5) | | (7.7) | | (3.8) | |
| WW | 159 | | | 180 | | | (11.7) | | (8.8) | | (2.9) | |
| | | | | | | |
INVEGA SUSTENNA / XEPLION / INVEGA
TRINZA / TREVICTA | | | | | | | |
| US | 796 | | | 733 | | | 8.6 | | 8.6 | | — | |
| Intl | 267 | | | 278 | | | (4.0) | | (1.8) | | (2.2) | |
| WW | 1,063 | | | 1,011 | | | 5.1 | | 5.7 | | (0.6) | |
| | | | | | | |
| SPRAVATO | | | | | | | |
| US | 269 | | | 180 | | | 50.1 | | 50.1 | | — | |
| Intl | 28 | | | 26 | | | 7.1 | | 12.5 | | (5.4) | |
| WW | 297 | | | 206 | | | 44.6 | | 45.3 | | (0.7) | |
| | | | | | | |
| OTHER NEUROSCIENCE | | | | | | | |
| US | 49 | | | 71 | | | (31.0) | | (31.0) | | — | |
| Intl | 206 | | | 334 | | | (38.1) | | (35.4) | | (2.7) | |
| WW | 255 | | | 404 | | | (36.9) | | (34.6) | | (2.3) | |
| | | | | | | |
| ONCOLOGY | | | | | | | |
| US | 3,019 | | | 2,285 | | | 32.2 | | 32.2 | | — | |
| Intl | 2,476 | | | 2,334 | | | 6.1 | | 10.6 | | (4.5) | |
| WW | 5,497 | | | 4,618 | | | 19.0 | | 21.3 | | (2.3) | |
| | | | | | | |
| CARVYKTI | | | | | | | |
| US | 304 | | | 145 | | | * | * | — | |
| Intl | 31 | | | 13 | | | * | * | * |
| WW | 334 | | | 159 | | | * | * | * |
| | | | | | | |
| DARZALEX | | | | | | | |
| US | 1,799 | | | 1,395 | | | 28.9 | | 28.9 | | — | |
| Intl | 1,285 | | | 1,155 | | | 11.3 | | 17.0 | | (5.7) | |
| WW | 3,084 | | | 2,550 | | | 20.9 | | 23.5 | | (2.6) | |
| | | | | | | |
| ERLEADA | | | | | | | |
| US | 342 | | | 287 | | | 19.0 | | 19.0 | | — | |
| Intl | 442 | | | 361 | | | 22.4 | | 25.7 | | (3.3) | |
| WW | 784 | | | 647 | | | 20.9 | | 22.7 | | (1.8) | |
| | | | | | | |
| IMBRUVICA | | | | | | | |
| US | 250 | | | 255 | | | (2.0) | | (2.0) | | — | |
| Intl | 481 | | | 533 | | | (9.6) | | (6.8) | | (2.8) | |
| WW | 731 | | | 788 | | | (7.2) | | (5.2) | | (2.0) | |
| | | | | | | |
| TECVAYLI | | | | | | | |
| US | 108 | | | 102 | | | 5.6 | | 5.6 | | — | |
| Intl | 38 | | | 24 | | | 59.9 | | 71.6 | | (11.7) | |
| WW | 146 | | | 126 | | | 15.8 | | 18.0 | | (2.2) | |
| | | | | | | |
| ZYTIGA / abiraterone acetate | | | | | | | |
| US | 9 | | | 9 | | | (7.3) | | (7.3) | | — | |
| Intl | 127 | | | 191 | | | (33.6) | | (30.7) | | (2.9) | |
| WW | 135 | | | 201 | | | (32.4) | | (29.6) | | (2.8) | |
| | | | | | | |
| OTHER ONCOLOGY | | | | | | | |
| US | 208 | | | 90 | | | * | * | — | |
| Intl | 74 | | | 58 | | | 25.5 | | 30.6 | | (5.1) | |
| WW | 282 | | | 148 | | | 90.4 | | 92.4 | | (2.0) | |
See footnotes at end of schedule
Johnson & Johnson
Segment sales
(Dollars in Millions)
| | | | | | | | | | | | | | | | | | | | | | | |
| FOURTH QUARTER |
| | | | | % Change |
| 2024 | | 2023 | | Reported | Operational(1) | Currency |
INNOVATIVE MEDICINE SEGMENT(2)(Continued) | | | | | | | |
| PULMONARY HYPERTENSION | | | | | | | |
| US | $ | 819 | | | 733 | | | 11.6 | % | 11.6 | % | — | % |
| Intl | 274 | | | 282 | | | (3.2) | | 1.2 | | (4.4) | |
| WW | 1,092 | | | 1,017 | | | 7.4 | | 8.7 | | (1.3) | |
| | | | | | | |
| OPSUMIT | | | | | | | |
| US | 385 | | | 368 | | | 4.8 | | 4.8 | | — | |
| Intl | 160 | | | 169 | | | (5.2) | | (2.5) | | (2.7) | |
| WW | 545 | | | 536 | | | 1.7 | | 2.5 | | (0.8) | |
| | | | | | | |
| UPTRAVI | | | | | | | |
| US | 391 | | | 348 | | | 12.3 | | 12.3 | | — | |
| Intl | 75 | | | 70 | | | 5.7 | | 11.2 | | (5.5) | |
| WW | 465 | | | 419 | | | 11.2 | | 12.1 | | (0.9) | |
| | | | | | | |
| OTHER PULMONARY HYPERTENSION | | | | | | | |
| US | 42 | | | 18 | | | * | * | — | |
| Intl | 40 | | | 45 | | | (10.0) | | (0.4) | | (9.6) | |
| WW | 82 | | | 61 | | | 32.3 | | 39.3 | | (7.0) | |
| | | | | | | |
| CARDIOVASCULAR / METABOLISM / OTHER | | | | | | | |
| US | 805 | | 652 | | 23.3 | | 23.3 | | — | |
| Intl | 153 | | 185 | | (17.6) | | (15.1) | | (2.5) | |
| WW | 957 | | 837 | | 14.3 | | 14.8 | | (0.5) | |
| | | | | | | |
| XARELTO | | | | | | | |
| US | 676 | | | 525 | | | 28.5 | | 28.5 | | — | |
| Intl | — | | | — | | | — | | — | | — | |
| WW | 676 | | | 525 | | | 28.5 | | 28.5 | | — | |
| | | | | | | |
| OTHER | | | | | | | |
| US | 130 | | | 127 | | | 1.5 | | 1.5 | | — | |
| Intl | 153 | | | 185 | | | (17.6) | | (15.1) | | (2.5) | |
| WW | 281 | | | 312 | | | (9.8) | | (8.3) | | (1.5) | |
| | | | | | | |
| TOTAL INNOVATIVE MEDICINE | | | | | | | |
| US | 8,977 | | 8,079 | | 11.1 | | 11.1 | | — | |
| Intl | 5,355 | | 5,643 | | (5.1) | | (1.0) | | (4.1) | |
| WW | $ | 14,332 | | | 13,722 | | 4.4 | % | 6.1 | % | (1.7) | % |
See footnotes at end of schedule
Johnson & Johnson
Segment sales
(Dollars in Millions)
| | | | | | | | | | | | | | | | | | | | | | | |
| FOURTH QUARTER |
| | | | | % Change |
| 2024 | | 2023 | | Reported | Operational(1) | Currency |
MEDTECH SEGMENT(2) | | | | | | | |
CARDIOVASCULAR(4) | | | | | | | |
| US | $ | 1,221 | | | 971 | | | 25.8 | % | 25.8 | % | — | % |
| Intl | 841 | | | 698 | | | 20.6 | | 22.0 | | (1.4) | |
| WW | 2,062 | | | 1,669 | | | 23.6 | | 24.2 | | (0.6) | |
| | | | | | | |
| ELECTROPHYSIOLOGY | | | | | | | |
| US | 681 | | | 667 | | | 2.1 | | 2.1 | | — | |
| Intl | 640 | | | 572 | | | 11.7 | | 13.3 | | (1.6) | |
| WW | 1,321 | | | 1,239 | | | 6.6 | | 7.3 | | (0.7) | |
| | | | | | | |
| ABIOMED | | | | | | | |
| US | 308 | | | 276 | | | 11.3 | | 11.3 | | — | |
| Intl | 77 | | | 64 | | | 19.8 | | 21.1 | | (1.3) | |
| WW | 384 | | | 340 | | | 12.9 | | 13.2 | | (0.3) | |
| | | | | | | |
SHOCKWAVE(5) | | | | | | | |
| US | 202 | | | — | | | * | * | — | |
| Intl | 56 | | | — | | | * | * | — | |
| WW | 258 | | | — | | | * | * | — | |
| | | | | | | |
OTHER CARDIOVASCULAR(4) | | | | | | | |
| US | 31 | | | 28 | | | 11.1 | | 11.1 | | — | |
| Intl | 68 | | | 61 | | | 12.1 | | 12.3 | | (0.2) | |
| WW | 99 | | | 89 | | | 11.8 | | 12.0 | | (0.2) | |
| | | | | | | |
| ORTHOPAEDICS | | | | | | | |
| US | 1,460 | | | 1,425 | | | 2.4 | | 2.4 | | — | |
| Intl | 856 | | | 843 | | | 1.6 | | 2.5 | | (0.9) | |
| WW | 2,315 | | | 2,268 | | | 2.1 | | 2.5 | | (0.4) | |
| | | | | | | |
| HIPS | | | | | | | |
| US | 272 | | | 266 | | | 2.5 | | 2.5 | | — | |
| Intl | 146 | | | 132 | | | 10.6 | | 11.7 | | (1.1) | |
| WW | 418 | | | 398 | | | 5.2 | | 5.6 | | (0.4) | |
| | | | | | | |
| KNEES | | | | | | | |
| US | 238 | | | 242 | | | (1.5) | | (1.5) | | — | |
| Intl | 160 | | | 144 | | | 10.7 | | 11.3 | | (0.6) | |
| WW | 398 | | | 387 | | | 3.1 | | 3.3 | | (0.2) | |
| | | | | | | |
| TRAUMA | | | | | | | |
| US | 514 | | | 487 | | | 5.5 | | 5.5 | | — | |
| Intl | 250 | | | 255 | | | (1.9) | | (0.5) | | (1.4) | |
| WW | 764 | | | 741 | | | 3.0 | | 3.5 | | (0.5) | |
| | | | | | | |
| SPINE, SPORTS & OTHER | | | | | | | |
| US | 434 | | | 430 | | | 1.1 | | 1.1 | | — | |
| Intl | 300 | | | 311 | | | (3.6) | | (2.9) | | (0.7) | |
| WW | 735 | | | 742 | | | (0.9) | | (0.6) | | (0.3) | |
See footnotes at end of schedule
Johnson & Johnson
Segment sales
(Dollars in Millions)
| | | | | | | | | | | | | | | | | | | | | | | |
| FOURTH QUARTER |
| | | | | % Change |
| 2024 | | 2023 | | Reported | Operational(1) | Currency |
MEDTECH SEGMENT(2)(Continued) | | | | | | | |
| SURGERY | | | | | | | |
| US | $1,038 | | | 1,047 | | | (0.9) | % | (0.9) | % | — | % |
| Intl | 1,469 | | | 1,484 | | | (1.0) | | 1.4 | | (2.4) | |
| WW | 2,507 | | | 2,530 | | | (0.9) | | 0.4 | | (1.3) | |
| | | | | | | |
| ADVANCED | | | | | | | |
| US | 478 | | | 468 | | | 2.0 | | 2.0 | | — | |
| Intl | 673 | | | 698 | | | (3.6) | | (1.6) | | (2.0) | |
| WW | 1,151 | | | 1,167 | | | (1.4) | | (0.1) | | (1.3) | |
| | | | | | | |
| GENERAL | | | | | | | |
| US | 560 | | | 579 | | | (3.1) | | (3.1) | | — | |
| Intl | 795 | | | 785 | | | 1.4 | | 4.0 | | (2.6) | |
| WW | 1,357 | | | 1,364 | | | (0.5) | | 1.0 | | (1.5) | |
| | | | | | | |
| VISION | | | | | | | |
| US | 509 | | | 487 | | | 4.5 | | 4.5 | | — | |
| Intl | 794 | | | 721 | | | 10.2 | | 12.2 | | (2.0) | |
| WW | 1,303 | | | 1,208 | | | 7.9 | | 9.1 | | (1.2) | |
| | | | | | | |
| CONTACT LENSES / OTHER | | | | | | | |
| US | 396 | | | 374 | | | 6.0 | | 6.0 | | — | |
| Intl | 541 | | | 508 | | | 6.4 | | 8.5 | | (2.1) | |
| WW | 937 | | | 882 | | | 6.3 | | 7.4 | | (1.1) | |
| | | | | | | |
| SURGICAL | | | | | | | |
| US | 113 | | | 114 | | | (0.4) | | (0.4) | | — | |
| Intl | 252 | | | 212 | | | 19.3 | | 21.1 | | (1.8) | |
| WW | 365 | | | 326 | | | 12.4 | | 13.6 | | (1.2) | |
| | | | | | | |
| TOTAL MEDTECH | | | | | | | |
| US | 4,227 | | | 3,930 | | | 7.6 | | 7.6 | | — | |
| Intl | 3,961 | | | 3,743 | | | 5.8 | | 7.6 | | (1.8) | |
| WW | $8,188 | | | 7,673 | | | 6.7 | % | 7.6 | % | (0.9) | % |
See footnotes at end of schedule
Johnson & Johnson
Segment sales
(Dollars in Millions)
| | | | | | | | | | | | | | | | | | | | | | | |
| TWELVE MONTHS |
| | | | | % Change |
| 2024 | | 2023 | | Reported | Operational(1) | Currency |
INNOVATIVE MEDICINE SEGMENT(2) | | | | | | | |
| IMMUNOLOGY | | | | | | | |
| US | $11,355 | | | 11,539 | | | (1.6) | % | (1.6) | % | — | % |
| Intl | 6,473 | | | 6,513 | | | (0.6) | | 4.0 | | (4.6) | |
| WW | 17,828 | | | 18,052 | | | (1.2) | | 0.4 | | (1.6) | |
| | | | | | | |
| REMICADE | | | | | | | |
| US | 1,009 | | | 1,143 | | | (11.7) | | (11.7) | | — | |
US Exports(3) | 98 | | | 147 | | | (33.0) | | (33.0) | | — | |
| Intl | 497 | | | 549 | | | (9.5) | | (5.0) | | (4.5) | |
| WW | 1,605 | | | 1,839 | | | (12.8) | | (11.4) | | (1.4) | |
| | | | | | | |
| SIMPONI / SIMPONI ARIA | | | | | | | |
| US | 1,082 | | | 1,124 | | | (3.8) | | (3.8) | | — | |
| Intl | 1,108 | | | 1,073 | | | 3.3 | | 13.2 | | (9.9) | |
| WW | 2,190 | | | 2,197 | | | (0.3) | | 4.5 | | (4.8) | |
| | | | | | | |
| STELARA | | | | | | | |
| US | 6,720 | | | 6,966 | | | (3.5) | | (3.5) | | — | |
| Intl | 3,641 | | | 3,892 | | | (6.4) | | (3.3) | | (3.1) | |
| WW | 10,361 | | | 10,858 | | | (4.6) | | (3.4) | | (1.2) | |
| | | | | | | |
| TREMFYA | | | | | | | |
| US | 2,443 | | | 2,147 | | | 13.7 | | 13.7 | | — | |
| Intl | 1,227 | | | 999 | | | 22.8 | | 27.6 | | (4.8) | |
| WW | 3,670 | | | 3,147 | | | 16.6 | | 18.1 | | (1.5) | |
| | | | | | | |
| OTHER IMMUNOLOGY | | | | | | | |
| US | 3 | | | 11 | | | (74.1) | | (74.1) | | — | |
| Intl | 0 | | | 0 | | | — | — | — |
| WW | 3 | | | 11 | | | (74.1) | | (74.1) | | — | |
| | | | | | | |
| INFECTIOUS DISEASES | | | | | | | |
| US | 1,354 | | | 1,500 | | | (9.8) | | (9.8) | | — | |
| Intl | 2,042 | | | 2,918 | | | (30.0) | | (29.3) | | (0.7) | |
| WW | 3,396 | | | 4,418 | | | (23.1) | | (22.7) | | (0.4) | |
| | | | | | | |
| COVID-19 VACCINE | | | | | | | |
| US | 0 | | | 0 | | | — | | — | | — | |
| Intl | 198 | | | 1,117 | | | (82.4) | | (82.4) | | 0.0 | |
| WW | 198 | | | 1,117 | | | (82.4) | | (82.4) | | 0.0 | |
| | | | | | | |
| EDURANT / rilpivirine | | | | | | | |
| US | 31 | | | 35 | | | (10.0) | | (10.0) | | — | |
| Intl | 1,241 | | | 1,115 | | | 11.2 | | 11.2 | | 0.0 | |
| WW | 1,272 | | | 1,150 | | | 10.6 | | 10.6 | | 0.0 | |
| | | | | | | |
| PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | | | | | | | |
| US | 1,311 | | | 1,446 | | | (9.4) | | (9.4) | | — | |
| Intl | 401 | | | 408 | | | (1.7) | | 1.1 | | (2.8) | |
| WW | 1,712 | | | 1,854 | | | (7.7) | | (7.1) | | (0.6) | |
| | | | | | | |
| OTHER INFECTIOUS DISEASES | | | | | | | |
| US | 11 | | | 19 | | | (41.0) | | (41.0) | | — | |
| Intl | 203 | | | 278 | | | (26.7) | | (23.9) | | (2.8) | |
| WW | 214 | | | 297 | | | (27.6) | | (25.0) | | (2.6) | |
See footnotes at end of schedule
Johnson & Johnson
Segment sales
(Dollars in Millions)
| | | | | | | | | | | | | | | | | | | | | | | |
| TWELVE MONTHS |
| | | | | % Change |
| 2024 | | 2023 | | Reported | Operational(1) | Currency |
INNOVATIVE MEDICINE SEGMENT(2)(Continued) | | | | | | | |
| NEUROSCIENCE | | | | | | | |
| US | $4,398 | | | 4,065 | | | 8.2 | % | 8.2 | % | — | % |
| Intl | 2,718 | | | 3,076 | | | (11.6) | | (7.8) | | (3.8) | |
| WW | 7,115 | | | 7,140 | | | (0.4) | | 1.3 | | (1.7) | |
| | | | | | | |
| CONCERTA / methylphenidate | | | | | | | |
| US | 134 | | | 230 | | | (41.7) | | (41.7) | | — | |
| Intl | 507 | | | 554 | | | (8.4) | | (4.1) | | (4.3) | |
| WW | 641 | | | 783 | | | (18.1) | | (15.1) | | (3.0) | |
| | | | | | | |
INVEGA SUSTENNA / XEPLION / INVEGA
TRINZA / TREVICTA | | | | | | | |
| US | 3,125 | | | 2,897 | | | 7.9 | | 7.9 | | — | |
| Intl | 1,097 | | | 1,218 | | | (9.9) | | (7.1) | | (2.8) | |
| WW | 4,222 | | | 4,115 | | | 2.6 | | 3.4 | | (0.8) | |
| | | | | | | |
| SPRAVATO | | | | | | | |
| US | 929 | | | 589 | | | 57.8 | | 57.8 | | — | |
| Intl | 148 | | | 100 | | | 48.2 | | 51.2 | | (3.0) | |
| WW | 1,077 | | | 689 | | | 56.4 | | 56.8 | | (0.4) | |
| | | | | | | |
| OTHER NEUROSCIENCE | | | | | | | |
| US | 210 | | | 349 | | | (39.8) | | (39.8) | | — | |
| Intl | 965 | | | 1,204 | | | (19.8) | | (15.1) | | (4.7) | |
| WW | 1,175 | | | 1,553 | | | (24.3) | | (20.7) | | (3.6) | |
| | | | | | | |
| ONCOLOGY | | | | | | | |
| US | 10,854 | | | 8,462 | | | 28.3 | | 28.3 | | — | |
| Intl | 9,926 | | | 9,199 | | | 7.9 | | 12.1 | | (4.2) | |
| WW | 20,781 | | | 17,661 | | | 17.7 | | 19.8 | | (2.1) | |
| | | | | | | |
| CARVYKTI | | | | | | | |
| US | 869 | | | 469 | | | 85.2 | | 85.2 | | — | |
| Intl | 94 | | | 30 | | | * | * | * |
| WW | 963 | | | 500 | | | 92.7 | | 92.7 | | 0.0 | |
| | | | | | | |
| DARZALEX | | | | | | | |
| US | 6,588 | | | 5,277 | | | 24.8 | | 24.8 | | — | |
| Intl | 5,082 | | | 4,467 | | | 13.8 | | 19.1 | | (5.3) | |
| WW | 11,670 | | | 9,744 | | | 19.8 | | 22.2 | | (2.4) | |
| | | | | | | |
| ERLEADA | | | | | | | |
| US | 1,282 | | | 1,065 | | | 20.3 | | 20.3 | | — | |
| Intl | 1,717 | | | 1,322 | | | 29.8 | | 32.9 | | (3.1) | |
| WW | 2,999 | | | 2,387 | | | 25.6 | | 27.3 | | (1.7) | |
| | | | | | | |
| IMBRUVICA | | | | | | | |
| US | 1,020 | | | 1,051 | | | (3.0) | | (3.0) | | — | |
| Intl | 2,018 | | | 2,214 | | | (8.8) | | (6.3) | | (2.5) | |
| WW | 3,038 | | | 3,264 | | | (6.9) | | (5.2) | | (1.7) | |
| | | | | | | |
| TECVAYLI | | | | | | | |
| US | 418 | | | 334 | | | 25.3 | | 25.3 | | — | |
| Intl | 131 | | | 61 | | | * | * | * |
| WW | 549 | | | 395 | | | 38.8 | | 39.8 | | (1.0) | |
| | | | | | | |
| ZYTIGA / abiraterone acetate | | | | | | | |
| US | 34 | | | 50 | | | (32.2) | | (32.2) | | — | |
| Intl | 597 | | | 837 | | | (28.6) | | (24.6) | | (4.0) | |
| WW | 631 | | | 887 | | | (28.8) | | (25.0) | | (3.8) | |
| | | | | | | |
| OTHER ONCOLOGY | | | | | | | |
| US | 643 | | | 215 | | | * | * | — | |
| Intl | 288 | | | 269 | | | 7.1 | | 10.4 | | (3.3) | |
| WW | 931 | | | 484 | | | 92.5 | | 94.3 | | (1.8) | |
See footnotes at end of schedule
Johnson & Johnson
Segment sales
(Dollars in Millions)
| | | | | | | | | | | | | | | | | | | | | | | |
| TWELVE MONTHS |
| | | | | % Change |
| 2024 | | 2023 | | Reported | Operational(1) | Currency |
INNOVATIVE MEDICINE SEGMENT(2)(Continued) | | | | | | | |
| PULMONARY HYPERTENSION | | | | | | | |
| US | $ | 3,143 | | | 2,697 | | | 16.5 | % | 16.5 | % | — | % |
| Intl | 1,140 | | | 1,117 | | | 2.0 | | 8.2 | | (6.2) | |
| WW | 4,282 | | | 3,815 | | | 12.3 | | 14.1 | | (1.8) | |
| | | | | | | |
| OPSUMIT | | | | | | | |
| US | 1,520 | | | 1,292 | | | 17.7 | | 17.7 | | — | |
| Intl | 664 | | | 681 | | | (2.4) | | 1.1 | | (3.5) | |
| WW | 2,184 | | | 1,973 | | | 10.7 | | 11.9 | | (1.2) | |
| | | | | | | |
| UPTRAVI | | | | | | | |
| US | 1,511 | | | 1,326 | | | 13.9 | | 13.9 | | — | |
| Intl | 307 | | | 255 | | | 20.1 | | 27.3 | | (7.2) | |
| WW | 1,817 | | | 1,582 | | | 14.9 | | 16.1 | | (1.2) | |
| | | | | | | |
| OTHER PULMONARY HYPERTENSION | | | | | | | |
| US | 112 | | | 79 | | | 41.8 | | 41.8 | | — | |
| Intl | 169 | | | 182 | | | (6.9) | | 8.2 | | (15.1) | |
| WW | 281 | | | 260 | | | 7.9 | | 18.3 | | (10.4) | |
| | | | | | | |
| CARDIOVASCULAR / METABOLISM / OTHER | | | | | | | |
| US | 2,866 | | 2,906 | | (1.4) | | (1.4) | | — | |
| Intl | 696 | | 765 | | (9.1) | | (7.1) | | (2.0) | |
| WW | 3,562 | | 3,671 | | (3.0) | | (2.6) | | (0.4) | |
| | | | | | | |
| XARELTO | | | | | | | |
| US | 2,373 | | | 2,365 | | | 0.3 | | 0.3 | | — | |
| Intl | — | | | — | | | — | | — | | — | |
| WW | 2,373 | | | 2,365 | | | 0.3 | | 0.3 | | — | |
| | | | | | | |
| OTHER | | | | | | | |
| US | 494 | | | 541 | | | (8.8) | | (8.8) | | — | |
| Intl | 696 | | | 765 | | | (9.1) | | (7.1) | | (2.0) | |
| WW | 1,189 | | | 1,306 | | | (8.9) | | (7.8) | | (1.1) | |
| | | | | | | |
| TOTAL INNOVATIVE MEDICINE | | | | | | | |
| US | 33,970 | | 31,169 | | 9.0 | | 9.0 | | — | |
| Intl | 22,994 | | 23,590 | | (2.5) | | 1.3 | | (3.8) | |
| WW | $ | 56,964 | | | 54,759 | | 4.0 | % | 5.7 | % | (1.7) | % |
See footnotes at end of schedule
Johnson & Johnson
Segment sales
(Dollars in Millions)
| | | | | | | | | | | | | | | | | | | | | | | |
| TWELVE MONTHS |
| | | | | % Change |
| 2024 | | 2023 | | Reported | Operational(1) | Currency |
MEDTECH SEGMENT(2) | | | | | | | |
CARDIOVASCULAR(4) | | | | | | | |
| US | $ | 4,513 | | | 3,633 | | | 24.2 | % | 24.2 | % | — | % |
| Intl | 3,194 | | | 2,717 | | | 17.6 | | 20.9 | | (3.3) | |
| WW | 7,707 | | | 6,350 | | | 21.4 | | 22.8 | | (1.4) | |
| | | | | | | |
| ELECTROPHYSIOLOGY | | | | | | | |
| US | 2,738 | | | 2,458 | | | 11.4 | | 11.4 | | — | |
| Intl | 2,529 | | | 2,230 | | | 13.4 | | 17.0 | | (3.6) | |
| WW | 5,267 | | | 4,688 | | | 12.3 | | 14.0 | | (1.7) | |
| | | | | | | |
| ABIOMED | | | | | | | |
| US | 1,213 | | | 1,066 | | | 13.7 | | 13.7 | | — | |
| Intl | 284 | | | 240 | | | 18.2 | | 20.3 | | (2.1) | |
| WW | 1,496 | | | 1,306 | | | 14.5 | | 14.9 | | (0.4) | |
| | | | | | | |
SHOCKWAVE(5) | | | | | | | |
| US | 442 | | | — | | | * | * | — | |
| Intl | 122 | | | — | | | * | * | — | |
| WW | 564 | | | — | | | * | * | — | |
| | | | | | | |
OTHER CARDIOVASCULAR(4) | | | | | | | |
| US | 120 | | | 109 | | | 10.7 | | 10.7 | | — | |
| Intl | 260 | | | 247 | | | 5.3 | | 7.3 | | (2.0) | |
| WW | 380 | | | 356 | | | 6.9 | | 8.4 | | (1.5) | |
| | | | | | | |
| ORTHOPAEDICS | | | | | | | |
| US | 5,689 | | | 5,525 | | | 3.0 | | 3.0 | | — | |
| Intl | 3,470 | | | 3,417 | | | 1.5 | | 3.0 | | (1.5) | |
| WW | 9,158 | | | 8,942 | | | 2.4 | | 3.0 | | (0.6) | |
| | | | | | | |
| HIPS | | | | | | | |
| US | 1,057 | | | 996 | | | 6.2 | | 6.2 | | — | |
| Intl | 581 | | | 564 | | | 3.0 | | 4.6 | | (1.6) | |
| WW | 1,638 | | | 1,560 | | | 5.0 | | 5.6 | | (0.6) | |
| | | | | | | |
| KNEES | | | | | | | |
| US | 922 | | | 896 | | | 2.9 | | 2.9 | | — | |
| Intl | 623 | | | 559 | | | 11.3 | | 12.4 | | (1.1) | |
| WW | 1,545 | | | 1,456 | | | 6.1 | | 6.5 | | (0.4) | |
| | | | | | | |
| TRAUMA | | | | | | | |
| US | 2,013 | | | 1,949 | | | 3.3 | | 3.3 | | — | |
| Intl | 1,036 | | | 1,030 | | | 0.6 | | 2.1 | | (1.5) | |
| WW | 3,049 | | | 2,979 | | | 2.3 | | 2.9 | | (0.6) | |
| | | | | | | |
| SPINE, SPORTS & OTHER | | | | | | | |
| US | 1,696 | | | 1,684 | | | 0.7 | | 0.7 | | — | |
| Intl | 1,230 | | | 1,263 | | | (2.6) | | (1.2) | | (1.4) | |
| WW | 2,926 | | | 2,947 | | | (0.7) | | (0.1) | | (0.6) | |
See footnotes at end of schedule
Johnson & Johnson
Segment sales
(Dollars in Millions)
| | | | | | | | | | | | | | | | | | | | | | | |
| TWELVE MONTHS |
| | | | | % Change |
| 2024 | | 2023 | | Reported | Operational(1) | Currency |
MEDTECH SEGMENT(2)(Continued) | | | | | | | |
| SURGERY | | | | | | | |
| US | $4,003 | | | 4,031 | | | (0.7) | % | (0.7) | % | — | % |
| Intl | 5,842 | | | 6,006 | | | (2.7) | | 0.6 | | (3.3) | |
| WW | 9,845 | | | 10,037 | | | (1.9) | | 0.1 | | (2.0) | |
| | | | | | | |
| ADVANCED | | | | | | | |
| US | 1,838 | | | 1,833 | | | 0.2 | | 0.2 | | — | |
| Intl | 2,650 | | | 2,837 | | | (6.6) | | (3.5) | | (3.1) | |
| WW | 4,488 | | | 4,671 | | | (3.9) | | (2.0) | | (1.9) | |
| | | | | | | |
| GENERAL | | | | | | | |
| US | 2,165 | | | 2,198 | | | (1.5) | | (1.5) | | — | |
| Intl | 3,192 | | | 3,168 | | | 0.8 | | 4.3 | | (3.5) | |
| WW | 5,358 | | | 5,366 | | | (0.2) | | 2.0 | | (2.2) | |
| | | | | | | |
| VISION | | | | | | | |
| US | 2,128 | | | 2,086 | | | 2.0 | | 2.0 | | — | |
| Intl | 3,018 | | | 2,986 | | | 1.1 | | 3.7 | | (2.6) | |
| WW | 5,146 | | | 5,072 | | | 1.5 | | 3.0 | | (1.5) | |
| | | | | | | |
| CONTACT LENSES / OTHER | | | | | | | |
| US | 1,684 | | | 1,626 | | | 3.6 | | 3.6 | | — | |
| Intl | 2,049 | | | 2,076 | | | (1.3) | | 1.8 | | (3.1) | |
| WW | 3,733 | | | 3,702 | | | 0.8 | | 2.6 | | (1.8) | |
| | | | | | | |
| SURGICAL | | | | | | | |
| US | 444 | | | 460 | | | (3.4) | | (3.4) | | — | |
| Intl | 969 | | | 910 | | | 6.5 | | 8.2 | | (1.7) | |
| WW | 1,413 | | | 1,370 | | | 3.2 | | 4.3 | | (1.1) | |
| | | | | | | |
| TOTAL MEDTECH | | | | | | | |
| US | 16,332 | | | 15,275 | | | 6.9 | | 6.9 | | — | |
| Intl | 15,525 | | | 15,125 | | | 2.6 | | 5.4 | | (2.8) | |
| WW | $31,857 | | | 30,400 | | | 4.8 | % | 6.2 | % | (1.4) | % |
Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
* Percentage greater than 100% or not meaningful
(1)Operational growth excludes the effect of translational currency
(2)Unaudited
(3)Reported as U.S. sales
(4)Previously referred to as Interventional Solutions
(5)Acquired on May 31, 2024
Supplemental sales information (unaudited)
(Dollars in Millions)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | FOURTH QUARTER |
| | | | | | % Change |
| | 2024 | | 2023 | | Total | Operations | Currency |
| Innovative Medicine | | | | | | | | |
| U.S. | | $ | 8,977 | | | 8,079 | | | 11.1 | % | 11.1 | | — | |
| International | | 5,355 | | | 5,643 | | | (5.1) | | (1.0) | | (4.1) | |
| Worldwide | | 14,332 | | | 13,722 | | | 4.4 | | 6.1 | | (1.7) | |
| | | | | | | | |
| COVID-19 Vaccine | | | | | | | | |
| U.S. | | — | | | — | | | — | | — | — |
| International | | — | | | 44 | | | * | * | * |
| Worldwide | | — | | | 44 | | | * | * | * |
| | | | | | | | |
| Innovative Medicine excluding COVID-19 Vaccine | | | | | | | | |
| U.S. | | 8,977 | | | 8,079 | | | 11.1 | | 11.1 | | — | |
| International | | 5,355 | | | 5,599 | | | (4.4) | | (0.3) | | (4.1) | |
| Worldwide | | 14,332 | | | 13,678 | | | 4.8 | | 6.5 | | (1.7) | |
| | | | | | | | |
| Worldwide | | | | | | | | |
| U.S. | | 13,204 | | | 12,009 | | | 10.0 | | 10.0 | | — | |
| International | | 9,316 | | | 9,386 | | | (0.7) | | 2.5 | | (3.2) | |
| Worldwide | | 22,520 | | | 21,395 | | | 5.3 | | 6.7 | | (1.4) | |
| | | | | | | | |
| COVID-19 Vaccine | | | | | | | | |
| U.S. | | — | | | — | | | — | | — | — |
| International | | — | | | 44 | | | * | * | * |
| Worldwide | | — | | | 44 | | | * | * | * |
| | | | | | | | |
| Worldwide | | | | | | | | |
| U.S. | | 13,204 | | | 12,009 | | | 10.0 | | 10.0 | | — | |
| International | | 9,316 | | | 9,342 | | | (0.3) | | 2.9 | | (3.2) | |
| Worldwide excluding COVID-19 Vaccine | | $ | 22,520 | | | 21,351 | | | 5.5 | | 6.9 | | (1.4) | |
| | | | | | | | |
| Europe | | $ | 4,921 | | | 4,962 | | | (0.8) | | (0.2) | | (0.6) | |
| Europe COVID-19 Vaccine Sales | | — | | | 44 | | | * | * | * |
| Europe excluding COVID-19 Vaccine | | $ | 4,921 | | | 4,918 | | | 0.1 | | 0.7 | | (0.6) | |
Note: Columns and rows within tables may not add due to rounding
* Percentage greater than 100% or not meaningful
Supplemental sales information (unaudited)
(Dollars in Millions)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | TWELVE MONTHS |
| | | | | | % Change |
| | 2024 | | 2023 | | Total | Operations | Currency |
| Innovative Medicine | | | | | | | | |
| U.S. | | $ | 33,970 | | | 31,169 | | | 9.0 | % | 9.0 | | — | |
| International | | 22,994 | | | 23,590 | | | (2.5) | | 1.3 | | (3.8) | |
| Worldwide | | 56,964 | | | 54,759 | | | 4.0 | | 5.7 | | (1.7) | |
| | | | | | | | |
| COVID-19 Vaccine | | | | | | | | |
| U.S. | | — | | | — | | | — | | — | | — | |
| International | | 198 | | | 1,117 | | | (82.4) | | (82.4) | | 0.0 | |
| Worldwide | | 198 | | | 1,117 | | | (82.4) | | (82.4) | | 0.0 | |
| | | | | | | | |
| Innovative Medicine excluding COVID-19 Vaccine | | | | | | | | |
| U.S. | | 33,970 | | | 31,169 | | | 9.0 | | 9.0 | | — | |
| International | | 22,796 | | | 22,473 | | | 1.4 | | 5.5 | | (4.1) | |
| Worldwide | | 56,766 | | | 53,642 | | | 5.8 | | 7.5 | | (1.7) | |
| | | | | | | | |
| Worldwide | | | | | | | | |
| U.S. | | 50,302 | | | 46,444 | | | 8.3 | | 8.3 | | — | |
| International | | 38,519 | | | 38,715 | | | (0.5) | | 2.9 | | (3.4) | |
| Worldwide | | 88,821 | | | 85,159 | | | 4.3 | | 5.9 | | (1.6) | |
| | | | | | | | |
| COVID-19 Vaccine | | | | | | | | |
| U.S. | | — | | | — | | | — | | — | | — | |
| International | | 198 | | | 1,117 | | | (82.4) | | (82.4) | | 0.0 | |
| Worldwide | | 198 | | | 1,117 | | | (82.4) | | (82.4) | | 0.0 | |
| | | | | | | | |
| Worldwide | | | | | | | | |
| U.S. | | 50,302 | | | 46,444 | | | 8.3 | | 8.3 | | — | |
| International | | 38,321 | | | 37,598 | | | 1.9 | | 5.5 | | (3.6) | |
| Worldwide excluding COVID-19 Vaccine | | $ | 88,623 | | | 84,042 | | | 5.5 | % | 7.0 | | (1.5) | |
| | | | | | | | |
| Europe | | $ | 20,212 | | | 20,410 | | | (1.0) | % | (0.6) | | (0.4) | |
| Europe COVID-19 Vaccine Sales | | 198 | | | 1,117 | | | (82.4) | | (82.4) | | 0.0 | |
| Europe excluding COVID-19 Vaccine | | $ | 20,014 | | | 19,293 | | | 3.7 | % | 4.1 | | (0.4) | |
Note: Columns and rows within tables may not add due to rounding
v3.24.4
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Details
| Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDueNovember2028Member |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_StatementClassOfStockAxis=jnj_A3.20NotesDueNovember2032Member |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_StatementClassOfStockAxis=jnj_A3.350NotesDueNovember2036Member |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_StatementClassOfStockAxis=jnj_A3.550NotesDueNovember2044Member |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Dec 2024 to Jan 2025
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jan 2024 to Jan 2025
